Prof Langer is a world-renowned scientist and entrepreneur who was a driving force behind Moderna's mRNA nanoparticle Covid vaccine

Langer教授是世界知名的科学家和企业家，他是Moderna mRNA纳米粒子Covid疫苗的推动力

Prof Langer has joined HERVOLUTION to develop HERVs that are a novel untapped target in oncology and senescence related diseases

兰格教授已经加入了HERVOLUTION开发HERVs，这是肿瘤学和衰老相关疾病的一个新的未开发目标

Prof Langer's scientific knowledge and entrepreneurial expertise will help expedite HERVOLUTION's lead candidate into clinical development

兰格教授的科学知识和创业专业知识将有助于加快赫尔进化的领先候选人进入临床开发

COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S.

丹麦哥本哈根，2023年9月13日/PRNewswire/-HERVOLUTION Therapeutics（HERVOLUTION）（以前称为Prother ApS），一家开发针对人类内源性逆转录病毒（HERVs）的有效癌症免疫疗法的早期生物技术公司，今天宣布任命教授罗伯特S。

Langer, Sc D., as Chair of its Scientific Advisory Board (SAB)..

Langer，Sc D.，担任科学顾问委员会（SAB）主席。。

A pioneer in drug delivery and tissue engineering, Prof Langer is widely regarded for his decades of accomplishments and contributions to medicine and biotechnology. Drug development technologies that Prof Langer helped pioneer have laid the foundations for transformative medicines including the cancer drug bevacizumab (Avastin) and Moderna's mRNA Covid vaccine..

Langer教授是药物输送和组织工程的先驱，因其数十年的成就和对医学和生物技术的贡献而受到广泛认可。Langer教授帮助pioneer的药物开发技术为癌症药物贝伐单抗（Avastin）和Moderna的mRNA-Covid疫苗等转化药物奠定了基础。。

HERVs are well recognized as tumour specific antigens, but until now, have been undruggable. HERVOLUTION has overcome this challenge and developed a powerful technology that can stimulate both arms of the immune system, the humoral and cellular response, against this rogue antigen class.

HERV被公认为肿瘤特异性抗原，但到目前为止，已经无法药物治疗。进化已经克服了这一挑战，并开发了一种强大的技术，可以刺激免疫系统的双臂，体液和细胞反应，对抗这种流氓抗原类别。

Professor Robert S. Langer, newly appointed Chair of HERVOLUTION's Scientific Advisory Board, commented: 'Oncology needs a paradigm shift. Upon review of HERVOLUTION's data, I found the approach radically different to others; innovative with a compelling mechanism of action. The Company's platform involves an advanced immunogen design, delivered through the optimal modalities.

新任命的赫尔沃尔夫科学顾问委员会主席罗伯特·S·兰格教授评论说：“肿瘤学需要范式转变。在回顾了赫尔文的数据后，我发现这种方法与其他人完全不同；具有令人信服的行动机制的创新。该公司的平台涉及先进的免疫原设计，通过最佳模式提供。

I strongly believe that the Company's technology will be a game changer, and I look forward to working with HERVOLUTION for cancer treatment and beyond.' .

我坚信该公司的技术将改变游戏规则，我期待着与癌症治疗及其他方面的合作。

Dr Peter Holst, Founder and Chief Scientific Officer of HERVOLUTION, said: 'We are honoured to welcome Professor Langer as Chair of HERVOLUTION's Scientific Advisory Board. His work in drug delivery systems and RNA technologies has laid the foundation for an entire industry. Professor Langer's expertise and track record of success will be invaluable as we accelerate the development of our lead candidate, a first-in-class immunotherapy against solid tumours into clinical development.'.

HERVOLUTION的创始人兼首席科学官Peter Holst博士说：“我们很荣幸欢迎Langer教授担任HERVOLUTION科学顾问委员会主席。他在药物输送系统和RNA技术方面的工作为整个行业奠定了基础。Langer教授的专业知识和成功记录将是非常宝贵的，因为我们加速了我们的主要候选人的发展，这是一种针对实体瘤进入临床开发的一流免疫疗法。

Jordi Naval, Chief Executive Officer of HERVOLUTION, added: 'We believe there is an untapped universe of opportunities in the HERV space. HERVs are ancient remnants of viral infections and constitute 8% of our DNA. They are silent in normal tissues but become overexpressed in tumour cells. Beyond cancer, HERV expression is connected to senescence and other ageing processes.

HERVOLUTION首席执行官Jordi Naval补充说：“我们相信HERV空间中存在大量未开发的机会。HERV是病毒感染的古老残余物，占我们DNA的8%。它们在正常组织中沉默，但在肿瘤细胞中过表达。除癌症外，HERV表达与衰老和其他衰老过程有关。

Professor Langer's expertise and guidance will further allow us to explore the full potential of the HERV universe and expand our leadership position in the field. Our recent rebrand to HERVOLUTION Therapeutics reflects this vision.'.

兰格教授的专业知识和指导将进一步使我们能够探索HERV宇宙的全部潜力，并扩大我们在该领域的领导地位。我们最近对HERVOLUTION Therapeutics的重组反映了这一愿景。

Prof Langer is the co-founder of Moderna Therapeutics and Professor at the Massachusetts Institute of Technology (MIT). Prof Langer has authored more than 1,500 scientific papers and has over 1,400 issued and pending patents worldwide. Prof Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology, and medical device companies..

Langer教授是Moderna Therapeutics的联合创始人和麻省理工学院（MIT）的教授。Langer教授撰写了1500多篇科学论文，并在全球拥有1400多项已发布和正在申请的专利。兰格教授的专利已获得400多家制药，化学，生物技术和医疗器械公司的许可或分许可。。

He has received over 220 major awards and is one of three living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers.

他获得了220多项重大奖项，是同时获得美国国家科学奖章（2006年）和美国国家技术创新奖章（2011年）的三名在世人士之一。他还获得了2002年Charles Stark Draper奖，被认为相当于诺贝尔工程师奖。

Prof Langer is the youngest person to be elected to all three American science academies: the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. He is considered to be the founder of tissue engineering in regenerative medicine leading to many advancements in the creation of blood vessels and vascularised engineered muscle tissue..

兰格教授是美国三大科学院（美国国家科学院，美国国家工程院和美国国家医学院）当选的最年轻人。他被认为是再生医学组织工程的创始人，在血管和血管化工程肌肉组织的创建方面取得了许多进步。。

HERVOLUTION is the new name for InProTher, which was incubated at the BioInnovation Institute (BII) and seeded by the Novo Nordisk Foundation. In May 2023, the Company announced that it had raised €6 million in seed funding from private investors to date, to advance its lead drug candidate, IPT001.

HERVOLUTION是InProTher的新名称，它在生物创新研究所（BII）孵化并由诺和诺德基金会播种。2023年5月，该公司宣布迄今已从私人投资者筹集600万欧元的种子资金，以推进其主要候选药物IPT001。

About HERVOLUTION Therapeutics

关于HERVOLUTION疗法

HERVOLUTION Therapeutics (formerly InProTher Aps) is a biotechnology company based in Copenhagen, Denmark. The vision of HERVOLUTION is to lead the development of novel immunotherapies that target the Human Endogenous Retroviruses (HERVs) as tumour and senescence-specific antigens. HERVOLUTION will solve bottlenecks and unleash the full potential of immuno-oncology..

HERVOLUTION Therapeutics（以前称为Prother Aps）是一家位于丹麦哥本哈根的生物技术公司。HER进化的愿景是领导开发针对人类内源性逆转录病毒（HERV）作为肿瘤和衰老特异性抗原的新型免疫疗法。HERVOLUTION将解决瓶颈并充分发挥免疫肿瘤学的潜力。。

To date, HERVOLUTION has put in place a world-class scientific team and created an emerging product development pipeline, including a leading programme targeted to enter clinic in 2024.

迄今为止，HERVOLUTION已经建立了一个世界级的科学团队，并创建了一个新兴的产品开发管道，其中包括一个旨在2024年进入诊所的领先计划。

Initial investors in HERVOLUTION include the BioInnovation Institute (Novo Nordisk Foundation), Vaekstfonden (Denmark), the European Innovation Council Fund, and expert Business Angels.

HERVOLUTION的最初投资者包括生物创新研究所（诺和诺德基金会），Vaekstfonden（丹麦），欧洲创新理事会基金和专家商业天使。

For more information, please visit: Hervolutiontx.com

欲了解更多信息，请访问：Hervolutiontx.com

SOURCE HERVOLUTION Therapeutics

来源HERVOLUTION Therapeutics